Understanding the Diversity of Skin Cancers skincancer cancer oncology skin dermatology
Basal cell carcinomaThe cellular origin of skin cancer Introduction Skin cancers occur in all skin types. There are different varieties of skin cancer, including basal cell carcinoma , squamous cell carcinoma , and malignant melanoma.
The melanin is packaged into melanosomes, sacs of pigment, which are transferred to the keratinocytes. In POC, they are uniformly scattered throughout the keratinocytes but aggregated within the cells in Whites. Melanomas Melanomas are the third most common type of skin cancer. They make up less than one percent of skin cancers but are the cause of most deaths related to skin cancer. They are three times more likely to be diagnosed late in the natural history of the disease compared to Whites.
These are typically not areas that receive much solar exposure. In comparison, superficial spreading melanoma is the most frequently occurring type in Hispanics and Whites. Squamous cell carcinoma SCC is linked to lifetime solar exposure, especially in women. It is a rapidly growing skin cancer, commonly from a pre-existing scar or burns. SCCs are the most common skin cancer in Black Americans and Asian Indians but are in second place among Hispanics, Chinese, and Japanese Asians, among whom BCC leads.
Again, POC are falsely assumed to be at low risk for skin cancer and are not typically warned to look out for signs of this disease or counseled regarding preventive measures and their crucial importance. The cellular origin of skin cancer BCC is thought to arise from the basal cells of the epidermis, but some scientists postulate that the root sheath cells of the hair follicle are actually the cells of origin because these tumors arise mainly from hair-bearing skin.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
The women tackling the ‘woeful’ diversity in plumbingDespite a shortage of plumbers and heating system installers the industry is still dominated by men.
続きを読む »
Diablo 4 players plead for more build diversity as meta steadily becomes staleDiablo 4 players plead for more build diversity as meta steadily becomes stale DiabloIV Diablo4 Blizzard Diablo
続きを読む »
Women ditch foundation for 'filter in a bottle' serum that creates flawless skin'I've tried a few different tinted moisturizers in my lifetime and this one is by far my favorite. It adds the perfect glow and I will use this in place of my makeup this Summer'
続きを読む »
Aldi's £1.99 BB cream that makes skin look 'flawless' is back'It makes your skin feel so nice with a glow.'
続きを読む »
The value of pre-symptomatic genetic risk assessment for age-related macular degeneration: the Moran AMD Genetic Testing Assessment (MAGENTA) study—a study protocol for a randomized controlled trial - TrialsBackground Age-related macular degeneration (AMD) is an irreversible blinding eye condition with complex genetic and environmental etiologies. Genetic testing for AMD for previously identified multiple-risk single nucleotide polymorphisms can help determine an individual’s future susceptibility. However, such testing has been discouraged until evidence shows that providing such information to symptomatic or pre-symptomatic individuals will alter their disease course. Therefore, we designed this study to investigate whether knowledge of AMD risk could stimulate the adoption of a healthier lifestyle that could lower the incidence of AMD later in life. We hypothesize that pre-symptomatic individuals informed of a high genetic risk of AMD are more likely to make quantifiable, positive lifestyle changes relative to participants informed of lower genetic risk or randomized to deferred disclosure of genetic testing results. Methods The Moran AMD Genetic Testing Assessment (MAGENTA) study is a phase 2, single-center, prospective, double-masked, randomized controlled trial conducted at the John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA. Participants are randomized by a 3:1 allocation ratio to immediate and deferred disclosure groups and followed for 12 months. Skin, ocular, and serum carotenoid status, as well as nutritional and social surveys, are assessed at study visits. Skin carotenoid assessment is by resonance Raman spectroscopy and reflectance spectroscopy, ocular carotenoids are measured with Heidelberg Spectralis autofluorescence imaging and fluorescence lifetime imaging ophthalmoscopy (FLIO), and serum carotenoids are quantified using high-performance liquid chromatography. The primary outcome evaluates changes in skin carotenoid status in response to genetic risk disclosure. The secondary outcomes examine changes in ocular and serum carotenoid status in response to genetic risk disclosure. Also, we will correlate AMD genetic risk with base
続きを読む »